Cocrystal Pharma (COCP) grants 49,229 options to Co-CEO Martin

Rhea-AI Filing Summary

Cocrystal Pharma Co-CEO and CFO Martin James Joseph received a grant of 49,229 non-qualified stock options on January 9, 2026. These stock options give him the right to buy up to 49,229 shares of Cocrystal Pharma common stock at an exercise price of $1.1 per share, and they expire on January 9, 2036.

Half of the options will vest and become exercisable on January 9, 2027. The remaining half will vest in eight equal quarterly installments starting March 31, 2027, as long as he continues to serve as an officer of the company on each vesting date. The grant was approved by the board’s Compensation Committee under the company’s 2025 Equity Incentive Plan and was reported as a direct beneficial holding.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Martin James Joseph

Role Co-CEO and CFO

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	49,229	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 49,229 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin James Joseph

(Last) (First) (Middle)

4400 BISCAYNE BLVD

SUITE # 670

(Street)

MIAMI FL 33157

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)(1)	$1.1	01/09/2026		A		49,229		(1)	01/09/2036	Common Stock	49,229	$0	49,229	D

Explanation of Responses:

1. The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date.

	/s/ James Martin	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cocrystal Pharma (COCP) report for Martin James Joseph?

Cocrystal Pharma reported that its Co-CEO and CFO, Martin James Joseph, received 49,229 non-qualified stock options on January 9, 2026.

What is the exercise price and term of the new Cocrystal Pharma (COCP) stock options?

The non-qualified stock options have an exercise price of $1.1 per share and expire on January 9, 2036.

How do the 49,229 stock options granted to Cocrystal Pharma (COCP) Co-CEO vest?

For the 49,229 options, one-half vests on January 9, 2027, and the remaining half vests in eight equal quarterly installments beginning March 31, 2027, subject to continued service as an officer.

Under which plan were the new Cocrystal Pharma (COCP) stock options granted?

The options were granted under Cocrystal Pharma’s 2025 Equity Incentive Plan, as approved by the company’s Compensation Committee of the Board of Directors.

Is the reported Cocrystal Pharma (COCP) option grant a direct or indirect holding?

The Form 4 shows 49,229 stock options beneficially owned directly by Martin James Joseph following the reported transaction.

Why is the Cocrystal Pharma (COCP) stock option grant exempt under Section 16(b)?

The grant is described as exempt from Section 16(b) under Rule 16b-3, because it was approved by Cocrystal Pharma’s Compensation Committee of the Board of Directors.